Search clinical trials for: Immunological adjuvant

Total 23887 results

Bristol-Myers Squibb

Not yet recruiting

Observational Study of Muscle Invasive Urothelial Carcinoma Participants Treated With Adjuvant Nivolumab in France (URADJ)

Urothelial Carcinoma

France
Tianjin Medical University Cancer Institute and...

Not yet recruiting

Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

Pancreatic Cancer

China
The Affiliated Nanjing Drum Tower Hospital of Nanjing...

Recruiting

Single-arm Study of Nimotuzumab Combined With mFOLFIRNIOX as Postoperative Adjuvant Therapy in Pancreatic Cancer

Pancreatic Cancer

China
Regeneron Pharmaceuticals

Not yet recruiting

Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental Agents in Adult Participants With Peri-operative Stage III/IV Cutaneous Squamous Cell Carcinoma (CSCC)

Cutaneous Squamous Cell Carcinoma
Ji Yongling

Not yet recruiting

Radiation Therapy Followed by Tislelizumab and Anlotinib Aeoadjuvant/Adjuvant Therapy for Stage II-IIIA NSCLC

Non-Small Cell Lung Cancer
University of Utah

Not yet recruiting

Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma (NeoRelapse)

Melanoma

United States
7 Hills Pharma, LLC

Not yet recruiting

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Melanoma | Kidney Cancer | Renal Cell Carcinoma | Hepatocellular Carcinoma | Colorectal Cancer | NSCLC | Non Small Cell Lung Cancer | Skin Cancer | Metastasis | Advanced Solid Tumor | Advanced Cancer | Renal Cell Cancer | Hepatocellular Cancer | Mismatch Repair Deficiency | Pleural Mesothelioma | MSI-High | Anaplastic Lymphoma... and other conditions

United States
Barretos Cancer Hospital
Fundação de Amparo à Pesquisa do Estado de São Paulo; Farmoquimica S.A.; Hospital...

Not yet recruiting

Clinical Outcome and Biomarkers for Predicting Immunological Response in Patients Treated With Imiquimod

Biomarkers | HSIL, High-Grade Squamous Intraepithelial Lesions | Vaginal Microbiome
Wu Wenming
NeoCura

Not yet recruiting

XH001 Combination With Ipilimumab and Chemotherapy for Patients With Resected Pancreatic Cancer

Pancreatic Cancer

China
National Cancer Institute, Naples

Recruiting

Neo-adjuvant Chemo and Immunotherapy in The Pre-operAtive Treatment of Locally Advanced cholangIOcarciNoma

Cholangiocarcinoma

Italy
Hoffmann-La Roche

Recruiting

A Study of Adjuvant Atezolizumab or Atezolizumab Plus Tiragolumab in Solid Tumors With Resectable Disease With Intermediate-High Risk of Recurrence and High Tumor Mutational Burden (TMB-H) or Microsatellite Instability (MSI-H) (IMperator)

Solid Tumors

Spain
Sana'a University

Not yet recruiting

Clinical and Immunological Evaluation of HA in Treatment of Periodontitis

Periodontitis

Yemen
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Recruiting

Tislelizumab Combined With Chemotherapy Followed by Surgery Versus Up-front Surgery in Resectable Clinically Node-negative Head and Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

China
Chen Xiaoping

Recruiting

Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma

HCC

China
Chen Xiaoping

Recruiting

Triple vs. Dual Adjuvant Therapy Following Liver Resection for HCC.

HCC

China
Merck Sharp & Dohme LLC
ModernaTX, Inc.

Recruiting

A Study of Adjuvant V940 and Pembrolizumab in Renal Cell Carcinoma (V940-004)

Renal Cell Carcinoma

United States, Australia, Canada, Chile, Taiwan
Merck Sharp & Dohme LLC
Moderna TX

Recruiting

A Study of (Neo)Adjuvant V940 and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007)

Carcinoma, Squamous Cell | Skin Neoplasms

Chile, Australia, Israel, New Zealand
LiteVax BV
University Hospital, Ghent; HarmonyCR, Melle, Belgium

Recruiting

Safety, Tolerability, Immunogenicity and Immunological Mechanisms of TETRALITE, a Novel Seasonal Influenza Vaccine (TETRALITE-Ib)

Vaccination Reaction

Belgium
ETOP IBCSG Partners Foundation
AstraZeneca AG Switzerland

Not yet recruiting

A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer. (ADOPT-lung)

Non Small Cell Lung Cancer
Samsung Bioepis Co., Ltd.

Recruiting

A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy

Non-small Cell Lung Cancer Stage IIIA | Non-small Cell Lung Cancer Stage II

Korea, Republic of, Poland, Spain, Turkey
Hoffmann-La Roche

Recruiting

A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy (SKYSCRAPER-15)

Non-small Cell Lung Cancer (NSCLC)

Korea, Republic of, United States, China, Japan, Australia, Taiwan, Brazil, Argentina, Hong Kong
Chen Xiaoping

Recruiting

Adjuvant PD-1 Inhibitor for Patients With Early-stage Hepatocellular Carcinoma Following Microwave Ablation

Hepatocellular Carcinoma

China
First Affiliated Hospital of Wenzhou Medical University

Not yet recruiting

Tislelizumab Plus Chemotherapy as Postoperative Adjuvant Therapy in Elderly Patients With LA GC/GEJC

Gastric Cancer
National Cancer Institute, Naples

Recruiting

A Phase I Trial of IMA970A Plus Montanide in Combination With Durvalumab (Anti-PD-L1)

Hepatocellular Carcinoma

Italy
University Medical Center Groningen
Merck Sharp & Dohme LLC

Recruiting

Neo-adjuvant Pembrolizumab as an Alternative Treatment for MMRd Uterine Cancer (PAM-II)

Endometrial Cancer

Netherlands
Regeneron Pharmaceuticals

Not yet recruiting

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-small Cell Lung Cancer That Can be Treated With Surgery.

Resectable Non-small Cell Lung Cancer
First Affiliated Hospital, Sun Yat-Sen University

Not yet recruiting

Multi-classifier System for Stratifying Stage III Papillary Renal Cell Carcinoma of Receiving Adjuvant Therapy

Papillary Renal Cell Carcinoma
Sun Yat-sen University

Recruiting

The Impact of Thymosin α-1 on the Efficacy of Concurrent Chemoradiotherapy Followed by Immunotherpay Consolidation for Locally Advanced NSCLC

Non-small Cell Lung Cancer

China
China Medical University, China

Not yet recruiting

Chemotherapy Sequential Tislelizumab After Radical Resection in Patients With dMMR/MSI-H or POLE/POLD1 Mutations

Colorectal Adenocarcinoma | Gastric

China
Gustave Roussy, Cancer Campus, Grand Paris
Merck Sharp & Dohme LLC

Not yet recruiting

Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab (NeoSarc)

Cancer

France
AstraZeneca
Daiichi Sankyo

Recruiting

A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer

Breast Cancer

Spain, China, United States, Italy, United Kingdom, Korea, Republic of, Belgium, France, Germany, Poland, Japan, Vietnam, Canada, Brazil, India, Malaysia, Taiwan, Thailand, Australia, Austria, Turkey, Hong Kong, Bulgaria, Switzerland, H... and more
Bristol-Myers Squibb

Recruiting

A Study to Evaluate Whether Participants With Melanoma Prefer Subcutaneous vs Intravenous Administration of Nivolumab and Nivolumab + Relatlimab Fixed-dose Combinations

Melanoma

Spain, United States, Italy, Chile, Greece, Argentina
Universitair Ziekenhuis Brussel

Not yet recruiting

A Clinical Trial on Combined (Neo-)Adjuvant Intravenous Plus Intracranial Administration of Ipilimumab and Nivolumab in Recurrent Glioblastoma (NEO-GLITIPNI)

Recurrent Glioblastoma

Belgium
Australasian Gastro-Intestinal Trials Group
The University of New South Wales; Walter and Eliza Hall Institute of Medical...

Recruiting

NEO-adjuvant Chemo-immunotherapy in Pancreatic Cancer (NEO-IMPACT)

Pancreatic Cancer

Australia
Beijing 302 Hospital

Recruiting

Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC

Liver Neoplasms

China
Guo Xufeng

Recruiting

Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma | Adjuvant Therapy | Neoadjuvant Chemoimmunotherapy

China
Beijing Friendship Hospital
Peking Union Medical College Hospital

Not yet recruiting

Neoadjuvant Chemoradiotherapy Combined With PD-1 Inhibitor and Thymalfasin for pMMR/MSS Locally Advanced Mid-low Rectal Cancer

Locally Advanced Rectal Cancer

China
Assistance Publique - Hôpitaux de Paris
AstraZeneca

Recruiting

Durvalumab/Tremelimumab in Neoadjuvant and Adjuvant Setting in Patients With HCC Treated by Electroporation Ablation (DUMELEP)

BCLC A Hepatocellular Carcinoma Non-resectable and Not Amenable for RFA

France
Peking Union Medical College Hospital

Not yet recruiting

Adjuvant Therapy for High-risk Hepatocellular Carcinoma Post Liver Transplantation

Liver Transplant; Complications | Recurrent Osteosarcoma | Hepatocarcinoma | High-Risk Cancer

China
Shanghai Minimally Invasive Surgery Center

Recruiting

Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX Regimen

Gastric Cancer Stage IIIB-IIIC

China
German Society for Pediatric Oncology and Hematology...
Deutsche Krebshilfe e.V., Bonn (Germany)

Recruiting

Nivolumab in Children and Adults With Nasopharyngeal Carcinoma (NPC-Nivo)

Nasopharyngeal Carcinoma | Nasopharyngeal Cancer | Nasopharynx Cancer | Nasopharyngeal Neoplasms

Germany
Roswell Park Cancer Institute

Recruiting

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Colo-rectal Cancer

United States
University of Alabama at Birmingham

Recruiting

Molecular Residual Disease (MRD) Guided Adjuvant ThErapy in Renal Cell Carcinoma (RCC) (MRD GATE RCC)

Renal Cell Carcinoma

United States
Affiliated Cancer Hospital of Shantou University...

Recruiting

Adjuvant Chemotherapy in Combination With Tislelizumab in Lymph Node-Positive Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell Carcinoma

China
NYU Langone Health

Recruiting

A Phase IB Study to Determine the Safety and Tolerability of Canakinumab and Tislelizumab in Combination With Nab-Paclitaxel and Gemcitabine in the Neo-adjuvant Treatment of Patients With Pancreatic Cancer

Pancreatic Cancer

United States
wang shusen

Recruiting

Trilaciclib in Patients With Early-Stage HR-negative Breast Cancer Receiving Adjuvant Chemotherapy (SMA-BC-002)

Breast Neoplasms

China
Genentech, Inc.
BioNTech SE

Recruiting

A Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Participants With Resected Pancreatic Ductal Adenocarcinoma (IMCODE003)

Adenocarcinoma, Pancreatic Ductal

United States
University of Southampton
AstraZeneca; Natera, Inc.

Recruiting

Developing ctDNA Guided Adjuvant Therapy for Gastrooesophageal Cancer (DECIPHER)

Gastrooesophageal Cancer

United Kingdom
AstraZeneca

Recruiting

Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE) (MDT-BRIDGE)

Non-small Cell Lung Cancer

Spain, Italy, France, Canada, Portugal, United States, Czechia, Germany, Sweden, Austria, Hungary
Guangxi Medical University

Not yet recruiting

Adjuvant Tislelizumab Plus Lenvatinib for Patients at High-risk of HCC Recurrence After Curative Resection or Ablation (PREVENT-2)

Recurrence | Hepatocellular Carcinoma | Immune Checkpoint Inhibitor

China

3

Subscribe